HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $3.75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Akebia Therapeutics (NASDAQ:AKBA) and maintained a price target of $3.75.
September 27, 2023 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akebia Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $3.75.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Akebia Therapeutics. This could potentially lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100